Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly and Deciphera in oncology development deal

This article was originally published in Scrip

Executive Summary

Lilly and Deciphera Pharmaceuticals are to study kinase inhibitors for potential first- and best-in-class anticancers in a deal worth up to $520 million. The two have signed a worldwide licensing agreement related to Deciphera's preclinical B-Raf kinase inhibitor programme, Phlomechanics, in four different project areas involving selective or multi-kinase targeted B-Raf inhibitors. B-Raf inhibitors are one of the most frequently mutated members of the kinase family across all cancers; the V600E mutant form in particular has been associated with increased tumour aggressiveness and decreased cancer rates. Lilly will make an up-front payment and provide research funding to Deciphera over the next two years. Deciphera could receive up to $130 million in development, regulatory and sales milestones for each of the projects. It will also be entitled to royalties on sales if a product is commercialised successfully. Lilly will gain exclusive worldwide rights to any products developed under the collaboration. The deal is another example of Lilly's efforts to boost its oncology portfolio, following its announcement that it was buying ImClone Systems (Scrip Online, October 7th, 2008).

You may also be interested in...



Innovation not M&A to drive Bayer growth in LatAm

Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.

2010 Scrip 100 - Is Anvisa a friend of innovators?

A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.

Elan raises $1.5 billion

Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.

Topics

Related Companies

UsernamePublicRestriction

Register

SC066183

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel